HJ Research delivers in-depth insights on the global HIV Therapeutics market in its upcoming report titled, Global HIV Therapeutics Market Report 2018-2029. According to this study, the global HIV Therapeutics market is estimated to be valued at XX Million US$ in 2023 and is projected to reach XX Million US$ by 2029, expanding at a CAGR of XX% during the forecast period. The report on HIV Therapeutics market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc.
This report studies the HIV Therapeutics market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in global HIV Therapeutics industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the HIV Therapeutics industry.
Global HIV Therapeutics market: competitive landscape analysis
This report contains the major manufacturers analysis of the global HIV Therapeutics industry. By understanding the operations of these manufacturers (revenue and gross margin from 2018 to 2023), the reader can understand the strategies and collaborations that the manufacturers are focusing on combat competition in the market.
Global HIV Therapeutics market: types and end industries analysis
The research report includes specific segments such as end industries and product types of HIV Therapeutics. The report provides market size for each type and end industry from 2018 to 2023. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Global HIV Therapeutics market: regional analysis
Geographically, this report is segmented into several key countries, with market size, growth rate of HIV Therapeutics in these countries from 2018 to 2023, which covering United States, Canada, Germany, France, UK, Italy, Russia, Spain, Netherlands, China, Japan, Korea, India, Australia, Indonesia, Vietnam, Turkey, Saudi Arabia, South Africa, Egypt, Brazil, Mexico, Argentina, Colombia.
Key players in global HIV Therapeutics market include:
Boehringer Ingelheim International GmbH
Merck & Co.
ViiV Healthcare
AbbVie
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb
Gilead Sciences
Johnson & Johnson
Cipla Limited
Market segmentation, by product types:
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Market segmentation, by applications:
Hospitals
Clinics
Labs
1 Industry Overview of HIV Therapeutics
1.1 Research Scope
1.2 Market Segmentation by Types of HIV Therapeutics
1.3 Market Segmentation by End Users of HIV Therapeutics
1.4 Market Dynamics Analysis of HIV Therapeutics
1.4.1 Market Drivers
1.4.2 Market Challenges
1.4.3 Market Opportunities
1.4.4 Porter’s Five Forces
2 Major Manufacturers Analysis of HIV Therapeutics Industry
2.1 Boehringer Ingelheim International GmbH
2.1.1 Company Overview
2.1.2 Main Products and Specifications
2.1.3 HIV Therapeutics Revenue and Gross Margin (2018-2023)
2.1.4 Contact Information
2.2 Merck & Co.
2.2.1 Company Overview
2.2.2 Main Products and Specifications
2.2.3 HIV Therapeutics Revenue and Gross Margin (2018-2023)
2.2.4 Contact Information
2.3 ViiV Healthcare
2.3.1 Company Overview
2.3.2 Main Products and Specifications
2.3.3 HIV Therapeutics Revenue and Gross Margin (2018-2023)
2.3.4 Contact Information
2.4 AbbVie
2.4.1 Company Overview
2.4.2 Main Products and Specifications
2.4.3 HIV Therapeutics Revenue and Gross Margin (2018-2023)
2.4.4 Contact Information
2.5 F. Hoffmann-La Roche Ltd.
2.5.1 Company Overview
2.5.2 Main Products and Specifications
2.5.3 HIV Therapeutics Revenue and Gross Margin (2018-2023)
2.5.4 Contact Information
2.6 Teva Pharmaceutical Industries Ltd.
2.6.1 Company Overview
2.6.2 Main Products and Specifications
2.6.3 HIV Therapeutics Revenue and Gross Margin (2018-2023)
2.6.4 Contact Information
2.7 Bristol-Myers Squibb
2.7.1 Company Overview
2.7.2 Main Products and Specifications
2.7.3 HIV Therapeutics Revenue and Gross Margin (2018-2023)
2.7.4 Contact Information
2.8 Gilead Sciences
2.8.1 Company Overview
2.8.2 Main Products and Specifications
2.8.3 HIV Therapeutics Revenue and Gross Margin (2018-2023)
2.8.4 Contact Information
2.9 Johnson & Johnson
2.9.1 Company Overview
2.9.2 Main Products and Specifications
2.9.3 HIV Therapeutics Revenue and Gross Margin (2018-2023)
2.9.4 Contact Information
2.10 Cipla Limited
2.10.1 Company Overview
2.10.2 Main Products and Specifications
2.10.3 HIV Therapeutics Revenue and Gross Margin (2018-2023)
2.10.4 Contact Information
3 Global HIV Therapeutics Market Analysis by Regions, Manufacturers, Types and End Users
3.1 Global Sales Revenue of HIV Therapeutics by Regions (2018-2023)
3.2 Global Sales Revenue of HIV Therapeutics by Manufacturers (2018-2023)
3.3 Global Sales Revenue of HIV Therapeutics by Types (2018-2023)
3.4 Global Sales Revenue of HIV Therapeutics by End Users (2018-2023)
4 Northern America HIV Therapeutics Market Analysis by Countries, Types and End Users
4.1 Northern America HIV Therapeutics Sales Revenue Analysis by Countries (2018-2023)
4.2 Northern America HIV Therapeutics Sales Revenue Analysis by Types (2018-2023)
4.3 Northern America HIV Therapeutics Sales Revenue Analysis by End Users (2018-2023)
4.4 United States HIV Therapeutics Sales Revenue Analysis (2018-2023)
4.5 Canada HIV Therapeutics Sales Revenue Analysis (2018-2023)
5 Europe HIV Therapeutics Market Analysis by Countries, Types and End Users
5.1 Europe HIV Therapeutics Sales Revenue Analysis by Countries (2018-2023)
5.2 Europe HIV Therapeutics Sales Revenue Analysis by Types (2018-2023)
5.3 Europe HIV Therapeutics Sales Revenue Analysis by End Users (2018-2023)
5.4 Germany HIV Therapeutics Sales Revenue Analysis (2018-2023)
5.5 France HIV Therapeutics Sales Revenue Analysis (2018-2023)
5.6 UK HIV Therapeutics Sales Revenue Analysis (2018-2023)
5.7 Italy HIV Therapeutics Sales Revenue Analysis (2018-2023)
5.8 Russia HIV Therapeutics Sales Revenue Analysis (2018-2023)
5.9 Spain HIV Therapeutics Sales Revenue Analysis (2018-2023)
5.10 Netherlands HIV Therapeutics Sales Revenue Analysis (2018-2023)
6 Asia Pacific HIV Therapeutics Market Analysis by Countries, Types and End Users
6.1 Asia Pacific HIV Therapeutics Sales Revenue Analysis by Countries (2018-2023)
6.2 Asia Pacific HIV Therapeutics Sales Revenue Analysis by Types (2018-2023)
6.3 Asia Pacific HIV Therapeutics Sales Revenue Analysis by End Users (2018-2023)
6.4 China HIV Therapeutics Sales Revenue Analysis (2018-2023)
6.5 Japan HIV Therapeutics Sales Revenue Analysis (2018-2023)
6.6 Korea HIV Therapeutics Sales Revenue Analysis (2018-2023)
6.7 India HIV Therapeutics Sales Revenue Analysis (2018-2023)
6.8 Australia HIV Therapeutics Sales Revenue Analysis (2018-2023)
6.9 Indonesia HIV Therapeutics Sales Revenue Analysis (2018-2023)
6.10 Vietnam HIV Therapeutics Sales Revenue Analysis (2018-2023)
7 Latin America HIV Therapeutics Market Analysis by Countries, Types and End Users
7.1 Latin America HIV Therapeutics Sales Revenue Analysis by Countries (2018-2023)
7.2 Latin America HIV Therapeutics Sales Revenue Analysis by Types (2018-2023)
7.3 Latin America HIV Therapeutics Sales Revenue Analysis by End Users (2018-2023)
7.4 Brazil HIV Therapeutics Sales Revenue Analysis (2018-2023)
7.5 Mexico HIV Therapeutics Sales Revenue Analysis (2018-2023)
7.6 Argentina HIV Therapeutics Sales Revenue Analysis (2018-2023)
7.7 Colombia HIV Therapeutics Sales Revenue Analysis (2018-2023)
8 Middle East & Africa HIV Therapeutics Market Analysis by Countries, Types and End Users
8.1 Middle East & Africa HIV Therapeutics Sales Revenue Analysis by Countries (2018-2023)
8.2 Middle East & Africa HIV Therapeutics Sales Revenue Analysis by Types (2018-2023)
8.3 Middle East & Africa HIV Therapeutics Sales Revenue Analysis by End Users (2018-2023)
8.4 Turkey HIV Therapeutics Sales Revenue Analysis (2018-2023)
8.5 Saudi Arabia HIV Therapeutics Sales Revenue Analysis (2018-2023)
8.6 South Africa HIV Therapeutics Sales Revenue Analysis (2018-2023)
8.7 Egypt HIV Therapeutics Sales Revenue Analysis (2018-2023)
9 Marketing Channel, Distributors and Traders Analysis
9.1 Marketing Channel
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Distributors and Traders
10 Global HIV Therapeutics Market Forecast by Regions, Countries, Manufacturers, Types and End Users
10.1 Global Sales Revenue Forecast of HIV Therapeutics by Regions (2024-2029)
10.2 Global Sales Revenue Forecast of HIV Therapeutics by Types (2024-2029)
10.3 Global Sales Revenue Forecast of HIV Therapeutics by End Users (2024-2029)
10.4 Global Revenue Forecast of HIV Therapeutics by Countries (2024-2029)
10.4.1 United States Revenue Forecast (2024-2029)
10.4.2 Canada Revenue Forecast (2024-2029)
10.4.3 Germany Revenue Forecast (2024-2029)
10.4.4 France Revenue Forecast (2024-2029)
10.4.5 UK Revenue Forecast (2024-2029)
10.4.6 Italy Revenue Forecast (2024-2029)
10.4.7 Russia Revenue Forecast (2024-2029)
10.4.8 Spain Revenue Forecast (2024-2029)
10.4.9 Netherlands Revenue Forecast (2024-2029)
10.4.10 China Revenue Forecast (2024-2029)
10.4.11 Japan Revenue Forecast (2024-2029)
10.4.12 Korea Revenue Forecast (2024-2029)
10.4.13 India Revenue Forecast (2024-2029)
10.4.14 Australia Revenue Forecast (2024-2029)
10.4.15 Indonesia Revenue Forecast (2024-2029)
10.4.16 Vietnam Revenue Forecast (2024-2029)
10.4.17 Brazil Revenue Forecast (2024-2029)
10.4.18 Mexico Revenue Forecast (2024-2029)
10.4.19 Argentina Revenue Forecast (2024-2029)
10.4.20 Colombia Revenue Forecast (2024-2029)
10.4.21 Turkey Revenue Forecast (2024-2029)
10.4.22 Saudi Arabia Revenue Forecast (2024-2029)
10.4.23 South Africa Revenue Forecast (2024-2029)
10.4.24 Egypt Revenue Forecast (2024-2029)
11 Industry Chain Analysis of HIV Therapeutics
11.1 Upstream Analysis of HIV Therapeutics
11.2 Downstream Major Consumers Analysis of HIV Therapeutics
11.3 Major Suppliers of HIV Therapeutics with Contact Information
11.4 Supply Chain Relationship Analysis of HIV Therapeutics
12 HIV Therapeutics New Project Investment Feasibility Analysis
12.1 HIV Therapeutics New Project SWOT Analysis
12.2 HIV Therapeutics New Project Investment Feasibility Analysis
12.2.1 Project Name
12.2.2 Investment Budget
12.2.3 Project Product Solutions
12.2.4 Project Schedule
13 HIV Therapeutics Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.2 References and Data Sources
14.2.1 Primary Sources
14.2.2 Secondary Paid Sources
14.2.3 Secondary Public Sources
14.3 Abbreviations and Units of Measurement
14.4 Author Details
14.5 Disclaimer
Table Types of HIV Therapeutics
Table End Users of HIV Therapeutics
Figure Market Drivers Analysis of HIV Therapeutics
Figure Market Challenges Analysis of HIV Therapeutics
Figure Market Opportunities Analysis of HIV Therapeutics
Table Market Drivers Analysis of HIV Therapeutics
Table Boehringer Ingelheim International GmbH Information List
Figure HIV Therapeutics Specifications of Boehringer Ingelheim International GmbH
Table HIV Therapeutics Revenue (Million USD) and Gross Margin of Boehringer Ingelheim International GmbH (2018-2023)
Figure HIV Therapeutics Revenue (Million USD) and Global Market Share of Boehringer Ingelheim International GmbH (2018-2023)
Table Merck & Co. Information List
Figure HIV Therapeutics Specifications of Merck & Co.
Table HIV Therapeutics Revenue (Million USD) and Gross Margin of Merck & Co. (2018-2023)
Figure HIV Therapeutics Revenue (Million USD) and Global Market Share of Merck & Co. (2018-2023)
Table ViiV Healthcare Information List
Figure HIV Therapeutics Specifications of ViiV Healthcare
Table HIV Therapeutics Revenue (Million USD) and Gross Margin of ViiV Healthcare (2018-2023)
Figure HIV Therapeutics Revenue (Million USD) and Global Market Share of ViiV Healthcare (2018-2023)
Table AbbVie Information List
Figure HIV Therapeutics Specifications of AbbVie
Table HIV Therapeutics Revenue (Million USD) and Gross Margin of AbbVie (2018-2023)
Figure HIV Therapeutics Revenue (Million USD) and Global Market Share of AbbVie (2018-2023)
Table F. Hoffmann-La Roche Ltd. Information List
Figure HIV Therapeutics Specifications of F. Hoffmann-La Roche Ltd.
Table HIV Therapeutics Revenue (Million USD) and Gross Margin of F. Hoffmann-La Roche Ltd. (2018-2023)
Figure HIV Therapeutics Revenue (Million USD) and Global Market Share of F. Hoffmann-La Roche Ltd. (2018-2023)
Table Teva Pharmaceutical Industries Ltd. Information List
Figure HIV Therapeutics Specifications of Teva Pharmaceutical Industries Ltd.
Table HIV Therapeutics Revenue (Million USD) and Gross Margin of Teva Pharmaceutical Industries Ltd. (2018-2023)
Figure HIV Therapeutics Revenue (Million USD) and Global Market Share of Teva Pharmaceutical Industries Ltd. (2018-2023)
Table Bristol-Myers Squibb Information List
Figure HIV Therapeutics Specifications of Bristol-Myers Squibb
Table HIV Therapeutics Revenue (Million USD) and Gross Margin of Bristol-Myers Squibb (2018-2023)
Figure HIV Therapeutics Revenue (Million USD) and Global Market Share of Bristol-Myers Squibb (2018-2023)
Table Gilead Sciences Information List
Figure HIV Therapeutics Specifications of Gilead Sciences
Table HIV Therapeutics Revenue (Million USD) and Gross Margin of Gilead Sciences (2018-2023)
Figure HIV Therapeutics Revenue (Million USD) and Global Market Share of Gilead Sciences (2018-2023)
Table Johnson & Johnson Information List
Figure HIV Therapeutics Specifications of Johnson & Johnson
Table HIV Therapeutics Revenue (Million USD) and Gross Margin of Johnson & Johnson (2018-2023)
Figure HIV Therapeutics Revenue (Million USD) and Global Market Share of Johnson & Johnson (2018-2023)
Table Cipla Limited Information List
Figure HIV Therapeutics Specifications of Cipla Limited
Table HIV Therapeutics Revenue (Million USD) and Gross Margin of Cipla Limited (2018-2023)
Figure HIV Therapeutics Revenue (Million USD) and Global Market Share of Cipla Limited (2018-2023)
Table Global Revenue (Million USD) of HIV Therapeutics by Regions (2018-2023)
Table Global Revenue (Million USD) of HIV Therapeutics by Manufacturers (2018-2023)
Table Global Revenue (Million USD) of HIV Therapeutics by Types (2018-2023)
Table Global Revenue (Million USD) of HIV Therapeutics by End Users (2018-2023)
Table Northern America HIV Therapeutics Revenue (Million USD) by Countries (2018-2023)
Table Northern America HIV Therapeutics Revenue (Million USD) by Types (2018-2023)
Table Northern America HIV Therapeutics Revenue (Million USD) by End Users (2018-2023)
Figure United States HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Canada HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Table Europe HIV Therapeutics Revenue (Million USD) by Countries (2018-2023)
Table Europe HIV Therapeutics Revenue (Million USD) by Types (2018-2023)
Table Europe HIV Therapeutics Revenue (Million USD) by End Users (2018-2023)
Figure Germany HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure France HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure UK HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Italy HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Russia HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Spain HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Netherlands HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Table Asia Pacific HIV Therapeutics Revenue (Million USD) by Countries (2018-2023)
Table Asia Pacific HIV Therapeutics Revenue (Million USD) by Types (2018-2023)
Table Asia Pacific HIV Therapeutics Revenue (Million USD) by End Users (2018-2023)
Figure China HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Japan HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Korea HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure India HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Australia HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Indonesia HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Vietnam HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Table Latin America HIV Therapeutics Revenue (Million USD) by Countries (2018-2023)
Table Latin America HIV Therapeutics Revenue (Million USD) by Types (2018-2023)
Table Latin America HIV Therapeutics Revenue (Million USD) by End Users (2018-2023)
Figure Brazil HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Mexico HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Argentina HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Colombia HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Table Middle East & Africa HIV Therapeutics Revenue (Million USD) by Countries (2018-2023)
Table Middle East & Africa HIV Therapeutics Revenue (Million USD) by Types (2018-2023)
Table Middle East & Africa HIV Therapeutics Revenue (Million USD) by End Users (2018-2023)
Figure Turkey HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Saudi Arabia HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure South Africa HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Figure Egypt HIV Therapeutics Revenue (Million USD) and Growth Rate (2018-2023)
Table Global Revenue (Million USD) Forecast of HIV Therapeutics by Regions (2024-2029)
Table Global Revenue (Million USD) Forecast of HIV Therapeutics by Types (2024-2029)
Table Global Revenue (Million USD) Forecast of HIV Therapeutics by End Users (2024-2029)
Table Major Consumers with Contact Information of HIV Therapeutics
Table Major Suppliers of HIV Therapeutics with Contact Information
Figure Supply Chain Relationship Analysis of HIV Therapeutics
Table New Project SWOT Analysis of HIV Therapeutics
Table Project Appraisal and Financing
Table New Project Construction Period
Table New Project Investment Feasibility Analysis of HIV Therapeutics
Table Research Programs/Design for This Report
Table Key Data Information from Primary Sources
Table Key Data Information from Secondary Sources
Table Part of Interviewees Record List of HIV Therapeutics Industry
Table Part of References List of HIV Therapeutics Industry
Table Units of Measurement List
Table Part of Author Details List of HIV Therapeutics Industry
HJ Research employs comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. At HJ Research, our researchers and domain experts use a unique blend of primary and secondary research, with validation and iterations at every stage, in order to minimize deviation and present the most accurate analysis of the HIV Therapeutics industry. Critical elements of methodology employed for all our studies include:
Secondary Sources:
The research team first works with national bureau of statistics, national customs, market research association, state information center, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Secondary sources are mainly from press releases, company reports and publications, non-profit organizations, industry associations, government publications, economic and demographic data and customs data. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Primary Research:
In the primary research process, for comprehensive understanding of the HIV Therapeutics market, it is essential to understand the complete value chain and in order to facilitate this, we collect data from HIV Therapeutics manufacturers, HIV Therapeutics raw material suppliers, HIV Therapeutics distributors as well as buyers. The primary sources from the supply side include HIV Therapeutics manufacturers, opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the HIV Therapeutics raw materials suppliers and producers, etc. The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users, and related key executives from various key companies and organizations operating in the global market.
Technical issues and trends are obtained from surveys, technical symposia and trade journals. Technical data is also gathered from intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered.
Statistical Model and Data Analysis:
Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, and industry experience and domain expertise. Qualitative analysis includes: HIV Therapeutics industry landscape and trends, HIV Therapeutics market dynamics and key issues, HIV Therapeutics technology landscape, market opportunities, porter’s analysis and PESTEL analysis, HIV Therapeutics competitive landscape and component benchmarking, policy and regulatory scenario. Quantitative analysis includes: HIV Therapeutics market size and forecast by regions, HIV Therapeutics market size and forecast by application, HIV Therapeutics market size and forecast by types, HIV Therapeutics company market share etc.
Quality Control:
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the HJ Research’s internal quality process.
